The composition of the main epitopes of the HIV envelope glycoprotein is constantly changed by mutation. Using this continues antigenic variation, HIV is able to overcome immunogenic recognition and elimination by the host. We have designed and synthesized a combination of five peptide constructs, representing each of the HIV-1 gp120 hypervariable epitopes. The vaccine construct was recognized by antibodies from HIV-1 positive individuals representing subtypes A, B, C, D, E and F, and from HIV-2 positive individuals from Africa. Immunization of rabbits and monkeys with the individual and complete vaccine preparation resulted in the induction of high titers of HIV-1 antibodies (> 1 year). This immunogen stimulates the production of antibodies which recognize and bind peptide analogs representing the sequences found in the HIV-1 variants tested. Immunization also induced T cell proliferative responses to the constructs and to five variable regions of HIV-1 RF, SF2 and MN, and HIV-1 V3 loop subtyping peptides. DTH reaction were also demonstrated in mice. Neutralization assays have shown that antibodies from the immunized animals are able to neutralize HIV-1 strains. Further tests using HIV-1 strains and primary isolates from pediatric patients are currently being performed. Since our data demonstrate the potential of this vaccine component, we are currently preparing this immunogen and a HIV DNA plasmid expressing several HIV proteins as a combination vaccine designed to induce both neutralizing antibodies and CTL responses.
|Original language||English (US)|
|State||Published - Mar 20 1998|
ASJC Scopus subject areas
- Agricultural and Biological Sciences (miscellaneous)
- Biochemistry, Genetics and Molecular Biology(all)
- Cell Biology